This proposal outlines a plan for a Phase 1b clinical trial for the injection of human spinal cord derived stem cells (HSSCs) into the cervical spinal cord of patients with ALS. This trial is a follow up to a trial already underway at Emory University, where 12 ALS patients have been injected with the same HSSCs into the lumbar spinal cord. In order to move this therapeutic approach closer to a clinical trial to determine if t is effective in ameliorating disease, we are proposing to test the safety of HSSC injection into the cervical spinal cord. Motor neurons in the cervical spinal cord innervate the respiratory diaphragm, the loss of which is typically the cause of death in ALS patients. We propose that the protection of these neurons is likely to prolong life by preserving respiratory function. This safety trial will employ progressive dose escalation to determine the maximum tolerated dose that can be used for the long term goal of performing Phase 2 and Phase 3 efficacy trials. There are two specific aims.
In Aim 1 we propose to sequentially escalate the dose of delivery as defined by 1) the number of cells/injection, 2) the number of injections into the cord, and 3) either unilateral or bilateral injections. This dose escalation scheme is designed to safely and efficiently test our ability to achieve a pre-defined target therapeutic dose, which can be used in the next phase of testing therapeutic efficacy.
Aim 2 of this proposal is to examine several exploratory endpoints that may be used to test the efficacy of this therapy in future Phase 2 and Phase 3 trials. These include measures of respiratory function, diaphragm function, muscle strength, and electrical characteristics of muscle (Electrical Impedance Myography). Successful completion of this Phase 1b trial will allow for testing of this highly innovative approach to the treatment of ALS. The impact will extend beyond patients with ALS since this novel trial will provide data on surgical approach and safety, as well as trial design that will be highly relevant to cellular therapeutics for spinal cord injury, multiple sclerosis, spinal muscular atrophies, as well as other neurological diseases.

Public Health Relevance

ALS is a devastating neurodegenerative disease with no effective treatments. Introduction of human spinal cord derived stem cells (HSSCs) into the spinal cord of ALS patients represents a potentially powerful way to prevent motor neuron death and prolong life. This Phase 1b trial will determine the safety of providing a Target Therapeutic Dose of HSSC injections into the cervical spinal cord of ALS patients, directed at preserving the motor neurons that control breathing. This Phase 1b trial is a necessary stepping stone toward more definitive therapeutic trials of HSSCs in patients with ALS.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
1R01NS077982-01A1
Application #
8440010
Study Section
Special Emphasis Panel (ZNS1-SRB-G (57))
Program Officer
Conwit, Robin
Project Start
2012-09-30
Project End
2016-07-31
Budget Start
2012-09-30
Budget End
2013-07-31
Support Year
1
Fiscal Year
2012
Total Cost
$595,628
Indirect Cost
$143,169
Name
Emory University
Department
Neurology
Type
Schools of Medicine
DUNS #
066469933
City
Atlanta
State
GA
Country
United States
Zip Code
30322
Glass, Jonathan D; Hertzberg, Vicki S; Boulis, Nicholas M et al. (2016) Transplantation of spinal cord-derived neural stem cells for ALS: Analysis of phase 1 and 2 trials. Neurology 87:392-400
Umoh, Mfon E; Fournier, Christina; Li, Yingjie et al. (2016) Comparative analysis of C9orf72 and sporadic disease in an ALS clinic population. Neurology 87:1024-30
Su, Feng-Chiao; Goutman, Stephen A; Chernyak, Sergey et al. (2016) Association of Environmental Toxins With Amyotrophic Lateral Sclerosis. JAMA Neurol 73:803-11
Goutman, Stephen A; Feldman, Eva L (2015) Clinical Trials of Therapies for Amyotrophic Lateral Sclerosis: One Size Does Not Fit All. JAMA Neurol 72:743-4
Paez-Colasante, Ximena; Figueroa-Romero, Claudia; Sakowski, Stacey A et al. (2015) Amyotrophic lateral sclerosis: mechanisms and therapeutics in the epigenomic era. Nat Rev Neurol 11:266-79
Tadesse, Tezeta; Gearing, Marla; Senitzer, David et al. (2014) Analysis of graft survival in a trial of stem cell transplant in ALS. Ann Clin Transl Neurol 1:900-8
Lunn, J Simon; Sakowski, Stacey A; Feldman, Eva L (2014) Concise review: Stem cell therapies for amyotrophic lateral sclerosis: recent advances and prospects for the future. Stem Cells 32:1099-109
Feldman, Eva L; Boulis, Nicholas M; Hur, Junguk et al. (2014) Intraspinal neural stem cell transplantation in amyotrophic lateral sclerosis: phase 1 trial outcomes. Ann Neurol 75:363-73
Riley, Jonathan; Glass, Jonathan; Feldman, Eva L et al. (2014) Intraspinal stem cell transplantation in amyotrophic lateral sclerosis: a phase I trial, cervical microinjection, and final surgical safety outcomes. Neurosurgery 74:77-87
Callaghan, Brian C; Kerber, Kevin A; Lisabeth, Lynda L et al. (2014) Role of neurologists and diagnostic tests on the management of distal symmetric polyneuropathy. JAMA Neurol 71:1143-9

Showing the most recent 10 out of 12 publications